The effect of Omega-3 on the serum visfatin concentration in patients with type II diabetes

Journal of Research in Medical Sciences

Volumn 16, Issue 4, 2011, Pages 490-495

  Hajianfar, Hossein ^a   Hosseinzadeh, Mohammad Javad ^a   Bahonar, Ahmad ^b   Mohammad, Kazem ^a   Askari, Golam Reza ^c   Entezari, Mohammad Hassan ^c   Keshavarz, Ali ^a   Ansari, Nazli ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes Mellitus; Fatty Acids; Nicotinamide Phosphoribosyltransferase; Omega 3; Type 2

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79957565388     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995--2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9): 1414-31.
2. Jung CH, Rhee EJ, Kim SY, Shin HS, Kim BJ, Sung KC, et al. Associations between two single nucleotide polymorphisms of adiponection gene and coronary artery diseases. Endocr J 2006; 53(5): 671-7.
3. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol 1988; 128(2): 389-401.
4. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115(5): 911-9; quiz 920.
5. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307(5708): 426-30.
6. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91(4): 1578-81.
7. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91(1): 295-9.
8. Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM, et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels. Diabetes 2006; 55(10): 2896-902.
9. Sun G, Bishop J, Khalili S, Vasdev S, Gill V, Pace D, et al. Serum visfatin concentrations are positively correlated with serum triacylglycerol and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 2007; 85(2): 399-404.
10. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ, et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids and inflammation. J Clin Endocrinol Metab 2007; 92(2): 666-72.
11. Wang P, van Greevenbroek MM, Bouwman FG, Brouwers MC, van der Kallen CJ, Smit E, et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 2007; 454(6): 971-6.
12. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007; 56(4): 565-70.
13. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178(3): 1748-58.
14. Tribole E. The ultimate Omega-3 diet: maximize the power of Omega-3s to supercharge your health, battle inflammation, and keep your mind sharp. 1st ed. New York: McGraw-Hill; 2007.
15. Shah M, Adams-Huet B, Brinkley L, Grundy SM, Garg A. Lipid, glycemic, and insulin responses to meals rich in saturated, cis-monounsaturated, and polyunsaturated (n-3 and n-6) fatty acids in subjects with type 2 diabetes. Diabetes Care 2007; 30(12): 2993-8.
16. Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 1998; 21(4): 494-500.
17. Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ. Modern nutrition in health and disease. 10th ed. New York: Lippincott Williams and Wilkins; 2005. p. 1053.
18. Simopoulos AP. Evolutionary aspects of diet, the Omega-6/Omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother 2006; 60(9): 502-7.
19. Lazar MA. How obesity causes diabetes: not a tall tale. Science 2005; 307(5708): 373-5.
20. Tanaka M, Nozaki M, Fukuhara A, Segawa K, Aoki N, Matsuda M, et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun 2007; 359(2): 194-201.
21. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre B-cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91(8): 3165-70.
22. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54(10): 2911-6.
23. Krzyzanowska K, Krugluger W, Mittermayer F, Rahman R, Haider D, Shnawa N, et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006; 110(5): 605-9.
24. Samara A, Pfister M, Marie B, Visvikis-Siest S. Visfatin, low-grade inflammation and body mass index (BMI). Clin Endocrinol (Oxf) 2008; 69(4); 568-74.
25. Haider DG, Pleiner J, Francesconi M, Wiesinger GF, Müller M, Wolzt M. Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab 2006; 91(11): 4702-4.
26. Wu LY, Juan CC, Ho LT, Hsu YP, Hwang LS. Effect of green tea supplementation on insulin sensitivity in Sprague-Dawley rats. J Agric Food Chem 2004; 52(3): 643-8.
27. Wolfram S, Raederstorff D, Preller M, Wang Y, Teixeira SR, Riegger C, et al. Epigallocatechin gallate supplementation alleviates diabetes in rodents. J Nutr 2006; 136(10): 2512-8.
28. Fukino Y, Shimbo M, Aoki N, Okubo T, Iso H. Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. J Nutr Sci Vitaminol (Tokyo) 2005; 51(5): 335-42.
29. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49(8): 1909-14.